



UNC CFAR Social and Behavioral Science Research Core  
SABI Database

**INSTRUMENT TITLE:** VAS: Visual Analogue Scale

**SOURCE ARTICLE:** Giordano, T. P.; Guzman, D.; Clark, R.; Charlebois, E. D.; Bangsberg, D. R. (2004). Measuring adherence to antiretroviral therapy in a diverse population using a visual analogue scale. *HIV Clinical Trials*, 5(2): 74-79.

**POPULATION:** Women, men, HIV-positive

**RESPONSE OPTIONS:** Put a cross on a number line from 0-100%.

**SCORING:** 0-100% adherent (worst to best).

**SURVEY ITEMS:** Please see below for formatted version.

**RELIABILITY INFORMATION:** No reliability information was reported.

**VALIDITY INFORMATION:** Criterion-related validity was assessed via comparison with unannounced pill counts.

**TERMS OF USE:**

Individuals may use this information for research or educational purposes only and may not use this information for commercial purposes. When using this instrument, please cite:

Giordano, T. P.; Guzman, D.; Clark, R.; Charlebois, E. D.; Bangsberg, D. R. (2004). Measuring adherence to antiretroviral therapy in a diverse population using a visual analogue scale. *HIV Clinical Trials*, 5(2): 74-79.

When presenting results using any survey information you obtained from the SABI, please acknowledge the University of North Carolina at Chapel Hill Center for AIDS Research (CFAR), an NIH funded program P30 AI50410.



UNC CFAR Social and Behavioral Science Research Core  
SABI Database

**Most people with HIV have many pills or other medications to take at different times during the day. Many people find it hard to always remember their pills or medicines. For example:**

- *Some people get busy and forget to carry their pills with them.*
- *Some people find it hard to take their pills according to all the instructions, such as “with food” or “on an empty stomach,” “every 8 hours,” or “with plenty of fluids.”*
- *Some people decide to skip pills to avoid side effects or to just not take pills that day.*

***We need to understand what people with HIV are really doing with their pills or medicines. Please tell us what you are actually doing. Don’t worry about telling us you don’t take all your pills or medicines. We need to know what is really happening, not what you think we “want to hear.”***

**Please put an “X” on the line at the point showing your best guess about how much of each medication you have taken in the last four weeks. We would be surprised if this was 100% for most people.**

**For example,  
0% means you have taken none of the medication in the last 4 weeks  
50% means you have taken half of that medicine  
100% means you have taken every single dose of the medicine**

**TERMS OF USE:**

Individuals may use this information for research or educational purposes only and may not use this information for commercial purposes. When using this instrument, please cite:

Giordano, T. P.; Guzman, D.; Clark, R.; Charlebois, E. D.; Bangsberg, D. R. (2004). Measuring adherence to antiretroviral therapy in a diverse population using a visual analogue scale. *HIV Clinical Trials*, 5(2): 74-79.


When presenting results using any survey information you obtained from the SABI, please acknowledge the University of North Carolina at Chapel Hill Center for AIDS Research (CFAR), an NIH funded program P30 AI50410.




UNC CFAR Social and Behavioral Science Research Core  
SABI Database

**VAS**


**38a1.** How about **(DRUG A)**?



**38b1.** How about **(DRUG B)**?



**38c1.** How about **(DRUG C)**?



**INTERVIEWER: TAKE BACK INSTRUMENT**

**TERMS OF USE:**

Individuals may use this information for research or educational purposes only and may not use this information for commercial purposes. When using this instrument, please cite:

Giordano, T. P.; Guzman, D.; Clark, R.; Charlebois, E. D.; Bangsberg, D. R. (2004). Measuring adherence to antiretroviral therapy in a diverse population using a visual analogue scale. *HIV Clinical Trials*, 5(2): 74-79.

When presenting results using any survey information you obtained from the SABI, please acknowledge the University of North Carolina at Chapel Hill Center for AIDS Research (CFAR), an NIH funded program P30 AI50410.